Renowned clinician, scientist and proven executive leader in biotechnology and healthcare with more than 25 years’ experience developing life-changing cellular medicines FLORHAM PARK, N.J., – September 15, 2021 — Celularity Inc. (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, today announced the appointment of Andrew L. Pecora, M.D., F.A.C.P., C.P.E., as President effective today. Reporting to Robert J. Hariri, M.D., Ph.D., Chairperson and Chief Executive Officer, Dr. Pecora will provide senior leadership to advance Celularity’s clinical pipeline toward U.S. Food and Drug Administration (FDA) approval, including responsibility for preclinical and clinical development and regulatory affairs. “It is...

Secured funding of approximately $138 million through merger and private placement investment in public equity (PIPE) financing Expanded Phase 1 clinical trial to include difficult-to-treat patient population Established multiple strategic and commercial partnerships Florham Park, NJ – August 16, 2021 – Celularity Inc. (“Celularity”) (Nasdaq:CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, today reported financial results for the quarter ended June 30, 2021, and provided a summary of recent corporate highlights. “This has been an exciting time for Celularity, with the achievement of multiple transformational milestones and significant progress in our unique approach to cellular medicine,” said Robert...

Pharmaceutical industry veteran brings more than 20 years of business and technical operations experience across various commercial and development products   FLORHAM PARK, N.J., – May 20, 2021 — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic  therapies derived from the postpartum human placenta, announced today the appointment of Bradley Glover, Ph.D., a global business and technical operations executive with more than 20 years of experience in the pharmaceutical industry, as Executive Vice President and Chief Technology Officer. At Celularity, Dr. Glover will be responsible for leading all aspects of...

NEW YORK, April 16, 2021 /PRNewswire/ — On April 14, 2021, GX Acquisition Corp. (“GX”) (NASDAQ: “GXGX”), provided information regarding a proposal to amend GX’s amended and restated certificate of incorporation (the “Charter”) to extend the date by which GX has to complete its initial business combination (the “Extension”) from May 23, 2021 to July 31, 2021. The Charter currently provides that GX has 24 months from the closing of its initial public offering (until May 23, 2021) to complete an initial business combination, which is customary for a special purpose acquisition company like GX. As previously announced, in January 2021 GX entered into a definitive merger agreement with Celularity...